

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)



(10) International Publication Number
WO 2021/155137 A1

(51) International Patent Classification:
C07K 14/005 (2006.01) *A61K 48/00* (2006.01)
C12N 15/86 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/015695

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
29 January 2021 (29.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/967,416 29 January 2020 (29.01.2020) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50
Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **FREDERICK, Amy**; c/o Genzyme Corpora-
tion, 50 Binney Street, Ambridge, Massachusetts 02142
(US). **JIN, Xiaoying**; c/o Genzyme Corporation, 50 Binney
Street, Cambridge, Massachusetts 02142 (US). **LIU, Lin**;
c/o Genzyme Corporation, 50 Binney Street, Cambridge,
Massachusetts 02142 (US). **O'RIORDAN, Catherine**; c/o
Genzyme Corporation, 50 Binney Street, Cambridge, Mass-
achusetts 02142 (US). **SULLIVAN, Jennifer**; c/o Gen-
zyme Corporation, 50 Binney Street, Cambridge, Massa-
chusetts 02142 (US).

(74) Agent: **VELEMA, James H.**; Lathrop GPM LLP, 28 State
Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MODIFIED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR OCULAR GENE THERAPY AND METHODS
OF USE THEREOF

(57) Abstract: Provided herein are modified adeno-associated viral (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, and nucleic acids encoding the capsid proteins. The AAV capsids provided herein confer retinal cell tropism and/or corneal cell tropism, and mediate improved transduction efficiency in clinically relevant ocular cell types such as photoreceptors and/or corneal endothelial cells. Also provided are nucleic acids encoding the capsid proteins, and AAV particles comprising the capsid proteins.



WO 2021/155137 A1